Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016', provides in depth analysis on Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) 
- The report reviews Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Overview 6
Therapeutics Development 7
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Stage of Development 7
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Therapy Area 8
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Indication 9
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Products under Development by Companies 12
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
OncoMed Pharmaceuticals, Inc. 19
PharmAbcine, Inc. 20
Sevion Therapeutics, Inc. 21
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Drug Profiles 22
ABT-165 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
demcizumab - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit DLL4 for Oncology - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
OMP-305B83 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
PMC-201 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Dormant Projects 36
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Discontinued Products 37
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Featured News & Press Releases 38
Sep 01, 2016: OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer 38
Jun 05, 2016: OncoMed Presents Phase 1b Data on demcizumab at the 2016 ASCO Annual Meeting 38
May 18, 2016: AbbVie To Present Data on ABT-165 at ASCO 2016 39
Apr 21, 2016: OncoMed Announces Clinical Data for Demcizumab to be Presented at the 2016 ASCO Annual Meeting 40
Apr 20, 2016: OncoMed Presents Demcizumab Mechanism Data at the AACR Annual Meeting 2016 40
Mar 17, 2016: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1) 41
Jan 22, 2016: OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium 42
Nov 09, 2015: OncoMed Presents Data From Anti-DLL4/VEGF Bispecific Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 43
Nov 07, 2015: OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting 44
Nov 04, 2015: OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting 44
Oct 27, 2015: OncoMed to present preclinical results from OMP-305B83 at the AACR-NCI-EORTC International Conference 45
Aug 10, 2015: OncoMed Pharmaceuticals Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data 45
Jun 01, 2015: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting 47
Jun 01, 2015: OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting 48
May 28, 2015: OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab During Conference Call on Tuesday, June 2, 2015 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17
Pipeline by AbbVie Inc, H2 2016 18
Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 19
Pipeline by PharmAbcine, Inc., H2 2016 20
Pipeline by Sevion Therapeutics, Inc., H2 2016 21
Dormant Projects, H2 2016 36
Discontinued Products, H2 2016 37